Industry News

Purdue Pharmaceuticals is expanding its new $25 million, 140,000-sf greenfield solid dosage manufacturing facility in Wilson, which ws completed in March 2000. Full-scale manufacturing is scheduled to begin by the second quarter of 2001. At full operation later this year, the facility will accommodate 150 employees. The Southeast Regional office of Clark, Richardson & Biskup Consulting Engineers Inc.

The Food and Drug Administration (FDA) in partnership with the General Services Administration (GSA) broke ground in March 2001 at the former Naval Surface Warfare Center on Phase 1a of the four-story, 114,000-gsf Center for Drug Evaluation and Research. Washington-based C&R Construction is performing the excavation work. The GSA has not yet awarded the Phase 1b construction contract, but completion of the facility is anticipated in fall 2002.

Tularik hopes to locate approximately 250,000 sf of research space to expand its drug discovery and development operations in the South San Francisco area, where the company is based. The biotechnology company expects to grow from 285 employees, currently housed in two locations, to over 300 in the year 2001.

Xanthon Inc. has proposed building a new 80,000-sf facility in the Research Triangle Park area; the company currently occupies approximately 24,000 sf in three buildings in the Park Research Center there. The structure will house a state-of-the-art lab for R&D, Class 100 and 10,000 cleanroom manufacturing suites, engineering labs, and administrative office space.

BioStratum has worked with Kansas City-based Clark, Richardson & Biskup Consulting Engineers Inc. (CRB) in the development of process descriptions, process flow diagrams, process analysis, and cell culture scale-up options for BioStratum's early phase development recombinant proteins that will be expressed in cell culture.